Glucocorticoid signaling is context-dependent, and in certain scenarios glucocorticoid receptors (GR) 31 are able to engage with other members of the nuclear receptor subfamily. Glucocorticoid signaling 32 can exert sexually dimorphic effects, suggesting a possible interaction with androgen sex hormones. 33
Glucocorticoids are adrenal steroid hormones engaged in a myriad of functions including adaptation 50 to stress, circadian function and immune regulation. Glucocorticoids also mediate quintessential 51 processes in metabolic physiology to ensure whole-body energy homeostasis e.g. by stimulating 52 hepatic gluconeogenesis, reducing peripheral glucose uptake and inducing adipose tissue lipolysis 53 (Kadmiel and Cidlowski 2013) . Due to the pleiotropic nature of glucocorticoid signaling, 54 dysregulation inevitably endangers metabolic health. This is seen in Cushing's syndrome, where 55 glucocorticoid excess causes massive accumulation and redistribution of energy stores, accompanied 56 by cardiometabolic harm (Morgan, et al. 2016) . 57
Glucocorticoid action in metabolism is predominantly mediated by glucocorticoid receptors (GR) 58 which are expressed in virtually all tissues in both humans and rodents. It is known that 59 glucocorticoid transcriptional activity is subject to multiple levels of regulation; from the production, 60 secretion and tissue uptake/export of steroid ligands to receptor expression and DNA-binding. 61
Intracellular enzymatic (in)activation controls glucocorticoid activity, i.e. 11B-hydroxysteroid 62 dehydrogenase type 1 (11B-HSD1) catalyzes glucocorticoid regeneration from inactive steroid while 63 11β-hydroxysteroid dehydrogenase type 2 (11B-HSD2) inactivates the active ligand pool. Active 64 ligand binding to GR provokes its translocation from the cytoplasm to the nucleus. GR binds DNA at 65 so-called glucocorticoid response elements thereby facilitating gene induction or repression 66 (Ratman, et al. 2013) . 67
The extent of GR-regulated transcriptional activity is dictated by ligand availability, receptor 68 expression and the DNA-binding site (Meijsing, et al. 2009 ), but also by interactions with 69 coregulatory proteins and other (often unknown) signaling partners (Meijer, et al. 2005) . 70
Glucocorticoids therefore act in a context-dependent manner and it was previously shown that 71 glucocorticoids can have sexually dimorphic actions (Duma, et al. 2010 ; Quinn and Cidlowski 2016). 72
For example, in the liver the synthetic glucocorticoid dexamethasone differentially affects expression 73 F o r R e v i e w O n l y 4 of many GR target genes in male vs. female rats (Duma et al. 2010) . Such sexually dimorphic effects 74 could possibly be explained by glucocorticoid interactions with sex hormone signaling, e.g. androgen 75 receptor (AR) activity. AR signaling is known to regulate physiological processes like adipose tissue 76 lipolysis and hepatic glucose and lipid metabolism (Lee, et al. 2013 ; Shen and Shi 2015), but it is yet 77 unclear if AR signaling can contribute to the sexually dimorphic effects of GR. 78 In certain contexts, GRs are able to engage with other members of the steroid nuclear receptor 79 subfamily (Chen, et al. 1997; Mifsud and Reul 2016) . All six nuclear steroid receptors, including the 80 GR and the AR, originate from a common ancestral receptor gene (Thornton 2001), which underlies 81 the substantial homology in DNA-binding domain and hormone-response elements. For example in 82 cancer, the chromatin binding landscape of the GR is exceptionally similar to that of other nuclear 83 steroid receptors (Severson, et al. 2018), GR shares numerous DNA binding sites with the AR (Arora, 84 et al. 2013) , and these two receptors may even form heterodimers on glucocorticoid response 85 elements (Chen et al. 1997 ). However, beyond cancer the crosstalk between GR and AR has 86 remained elusive. 87
In this study, we explored if crosstalk between androgens and glucocorticoids exists in metabolic 88 tissues. In male C57BL/6J mice, we investigated possible interactions in white adipose tissue (WAT), 89 liver, and brown adipose tissue (BAT) -all metabolically-active tissues that contribute considerably to 90 whole-body metabolism. We reveal that androgen signaling strongly influences metabolic GR 91 signaling, and that the underlying mechanisms are highly tissue-specific. 92 93
Material and methods 94
Animals 95
All animal studies were approved by the ethical committee of Leiden University Medical Center. 96
Mice were housed in conventional cages with a 12:12-hour light-dark cycle and ad libitum access to 97 F o r R e v i e w O n l y 5 food and water. To examine the effect of AR signaling on metabolic glucocorticoid action, 8-week old 98 male C57BL6/J mice (Jackson Laboratory) were exposed to the GR agonist corticosterone (CORT; 99 Sigma-Aldrich) and AR agonist dihydrotestosterone (DHT; 5α-Androstan-17β-ol-3-one, Sigma-100 Aldrich) via subcutaneous implantation of slow-release pellets (100 mg). The AR antagonist 101 Enzalutamide (MedChemExpress) was administered via diet-supplementation (357 mg drug per kg 102 diet; resulting in an estimated dose of 40 mg/kg/day). The following experimental groups were 103 followed for a period of 14 days: 1) Vehicle (N=6), 2) CORT (20 mg corticosterone; N=7), 3) 104 CORT+DHT (20 mg corticosterone, 30 mg DHT; N=7) and 4) CORT+Enza (20 mg corticosterone + 105 Enzalutamide-treatment; N=7). At baseline and after 14 days, body weight was measured with a 106 scale and body composition was determined by echo-MRI. After seven days of intervention, mice 107 were fasted for 6 hours and blood was collected for analysis of plasma triglycerides, cholesterol and 108 free fatty acids. After 14 days mice were euthanized by CO 2 inhalation, blood was drawn via heart 109 puncture in EDTA-coated tubes, mice were perfused with ice-cold PBS for 5 min and metabolic 110 organs (i.e. gonadal and subcutaneous WAT, liver, interscapular BAT) were collected for molecular, 111 functional and histological analyses. 112
To evaluate the effect of Enzalutamide alone, we performed a control experiment in which mice 113 were treated with vehicle (N=6) or Enzalutamide (40 mg/kg/day via diet; N=6) for 27 days. At 114 baseline and after 27 days, body weight was measured with a scale and body composition was 115 determined by echo-MRI. Blood was collected at day 21 after a 6 hour fast, for analysis of plasma 116 triglycerides, cholesterol and free fatty acids. After 27 days, mice were euthanized by CO 2 inhalation, 117 perfused with ice-cold PBS for 5 min and WAT and liver were collected for molecular analysis. 118
RNA isolation, cDNA synthesis and real-time quantitative (RT)-qPCR analysis 119
Snap-frozen tissue samples of gonadal WAT, liver and BAT were homogenized in Tripure (Roche) and 120 mRNA was isolated according to the manufacturer's protocol. 500-1000 ng mRNA was used for cDNA 121 
Cell culture 150
Human HEK293T cells were passaged in culture medium (DMEM+Glutamax supplemented with 10% 151 FCS and penicillin/streptomycin) and during experiments medium with charcoal-stripped serum was 152 used. Cells were transfected using Fugene HD (Promega) with 25 ng TAT3-luciferase, 10 ng human 153 AR or GR, 1 ng CAGGS-renilla and 100 ng pcDNA. Cells were pretreated with Enzalutamide for 30 min 154 before agonists for AR (Testosterone or DHT) or GR (cortisol) were added. After 24 hours, firefly-and 155 renilla-luciferase signals were measured using a dual-luciferase assay (Promega). 156
Murine 3T3.L1 cells were passaged in culture medium (DMEM+Glutamax supplemented with 10% 157 FCS and penicillin/streptomycin). For experiments, preadipocytes were seeded and medium was 158 replaced every 2-3 days. After reaching confluence, adipogenic differentiation was induced by 159 adding medium supplemented with 250 nM dexamethasone, 11 mg/ml IBMX and 10 mg/ml insulin 160 for 2 days, medium supplemented with 10 mg/mL insulin for 6 days and normal culture medium for 161 7 days. During the last 2 days of differentiation and during treatments FCS was replaced with 162 charcoal-stripped serum. Cells were pretreated with 100 nM DHT and after 1 hour 10-30 nM 163 corticosterone was added for 24 hours. Cells were harvested in Tripure for further RT-PCR analysis of 164 GR-responsive transcripts. Murine immortalized brown adipocytes were generated and cultured as 165 previously published (Kroon, et al. 2018 ) and exposure with DHT and corticosterone was identical as 166 in 3T3.L1 cells. 167
Statistical analysis 170
All data are presented as mean ± SEM. Statistical analysis were performed with GraphPad Prism 7 171 software (GraphPad Inc.). To calculate statistical differences between more than two groups, a one-172 way analysis of variance with Tukey multiple-comparison test was used. For direct comparison of 173 two groups, an unpaired students t-test was performed. 174
175
Results 176
Confirmation of glucocorticoid and androgen interventions 177
We set out to investigate the crosstalk between glucocorticoid and androgen signaling in metabolic 178 tissues. AR agonist DHT and AR antagonist Enzalutamide were used, for which reporter assays in 179 HEK293T cells confirmed effective AR agonism and antagonism, respectively ( Fig. 1A-B) . 180
Enzalutamide did not exhibit GR cross-reactivity ( Fig. 1C) (Dalal, et al. 2014 ). To investigate crosstalk 181 in vivo, male C57BL/6J mice were implanted with CORT-releasing pellets (van den Beukel, et al. Enzalutamide treatment (due to relieved negative feedback on testosterone secretion) confirm the 188 efficacy of experimental interventions (Fig. 1I-K) . 189
AR antagonism lowers glucocorticoid-induced hyperlipidemia 190
Elevated CORT did not influence total body weight but did alter body composition (seemingly 191 enhanced fat mass and significantly reduced lean mass; Fig. 2A ) and induced hyperlipidemia (Fig. 192 ). DHT generally did not affect CORT-induced metabolic outcome, with the exception of lean body 193 mass ( Fig. 2A) . Notably, concomitant AR antagonism with Enzalutamide significantly lowered 6 hour-194 fasted plasma levels of triglycerides (p<0.01 vs CORT), cholesterol (p<0.01 vs CORT) and free fatty 195 acids (p<0.05 vs CORT), thus alleviating CORT-induced dyslipidemia (Fig. 2B) . Treatment with 196
Enzalutamide alone did not alter body weight and composition (Fig. 2C) , but did lower plasma lipid 197 levels ( Fig. 2D) . (Fig. 3L) . Our data highlight the tissue-specific nature of 218 glucocorticoid-androgen interactions and a possible effect on metabolic pathways. 219
AR agonism potentiates GR signaling in fully differentiated murine (brown) adipocytes 220
To further investigate the crosstalk between androgens and glucocorticoids directly on adipocytes -221 we utilized cell-based culture models of immortalized white and brown adipocytes. We first 222 confirmed Nr3c1 and Nr3c4 expression in fully differentiated white and brown adipocytes ( Fig. 4A- induced expression of lipolysis gene Atgl was not significantly increased upon DHT treatment (Fig.  232   4F) . In brown adipocytes we observed a similar potentiation for expression of Fkbp5 (Fig. 4G) and 233
possibly Gilz (Fig. 4H) but not for Mt2a and Ucp1 (Fig. 4I-J) , supporting our observations in vivo in 234 BAT. Altogether we observe interactions between glucocorticoid and androgen signaling in vitro, as 235 androgens exposure potentiates GR activity at physiological glucocorticoid concentrations. 236
AR antagonism tissue-specifically alters corticosterone and 11-dehydrocorticosterone levels 237
We attempted to decipher how AR signaling alters GR-regulated transcriptional activity. GR 238 expression levels in WAT and liver were not causally involved: CORT downregulated GR protein 239 expression via homologous downregulation (Dong, et al. 1988 ), but androgen interventions did not 240 further affect GR expression (Fig 5A-D) . To analyze if glucocorticoid turnover is affected by androgen 241 (Fig. 6A) , AR antagonism significantly decreased CORT levels in WAT 243 (p<0.01, Fig. 6B ), while this was unaltered by AR agonism. In contrast to WAT, AR antagonism did not 244 influence hepatic CORT levels (Fig 6C) . Plasma and liver levels of the inactive glucocorticoid 245 metabolite 11-DHC were significantly increased upon AR blockade (Fig. 6D, F) , but were not changed 246 in WAT (Fig. 6E) . Androgen signaling thus seems to modulate glucocorticoid turnover, as the 247 CORT/11-DHC ratio in plasma, WAT and liver was consistently lower upon AR antagonism ( Fig. 6G-I) , 248 influencing tissue-specific glucocorticoid ligand levels. 249
AR antagonism decreases 11BHSD1 expression which underlies GR transcriptional activity in WAT 250
but not liver 251
The balance between active vs inactive glucocorticoids in the circulation is predominantly dictated 252 by peripheral and central 11BHSD1 activity and renal 11BHSD2 activity (Pereira, et al. 2012). Local 253 active glucocorticoid levels may however be skewed by tissue-specific 11BHSD1 activity, and to 254 explore if this contributes to altered glucocorticoid turnover upon AR blockage we analyzed mRNA 255 and protein expression of 11BHSD1. CORT upregulated hsd11b1 mRNA expression in WAT and liver 256 ( Fig. 7A-B) . In WAT, this upregulation was accompanied by increased 11BHSD1 protein expression 257 ( Fig. 7C) . Notably, this upregulation was abolished by AR blockade (p<0.05 for protein; Fig. 7C) , 258 suggesting that AR signaling influences glucocorticoid turnover in WAT. In liver, AR antagonism 259 attenuated CORT-induced hsd11b1 mRNA expression ( Fig. 7B) , but protein expression did not follow 260 this pattern (Fig. 7D) . We next analyzed if altered glucocorticoid turnover contributed to the reduced 261 GR-regulated transcriptional activity upon AR antagonism. Thereto we plotted tissue-specific CORT 262 concentrations against GR-responsive transcript expression, revealing that Fkbp5, Gilz and Mt2a 263 expression proportionally changed in parallel with ligand concentrations in WAT (Fig. 7E) . In contrast 264 to WAT, GR-regulated transcriptional activity in liver was altered independent of tissue CORT 265 Concerning the increased GR-target gene expression upon simultaneous CORT and DHT exposure, it 281 has to be noted that the enhanced GR-target gene expression observed upon DHT treatment may 282 either be the consequence of AR-mediated potentiation of GR signaling or it could be an additive 283 effect, reflecting the promiscuous nature of many GR-responsive transcripts that can also be AR-284 responsive. Our findings in cultured white and brown adipocytes show that DHT alone does not 285 induce Gilz and Mt2 expression, but that combined with CORT it synergistically enhances 286 transcription. This suggests that a potentiation of GR signaling by AR is responsible for the increased 287 transcription, rather than additive transcriptional effects of both receptors on shared GR-AR target 288 genes. On the other hand, Fkbp5 expression was slightly induced by DHT alone. Part of the effect 289 initially support a common goal -setting free energy substrates by e.g. lipolysis (Lee et al. 2013; 307 Peckett, et al. 2011) -but subsequently aids differential functions: energy mobilization to cope with 308 a stressful situation for glucocorticoids and generating fuel for anabolic growth for androgens. In our 309 studies, we indeed observe collaborative signaling between glucocorticoids and androgens in WAT -310 which has lipolytic capacity (Wang, et al. 2015) -but how glucocorticoid-androgen interplay affects 311 fuel-utilizing tissues is a subject for further study. 312
Our data indicate that androgens modulate glucocorticoid signaling via parallel, non-mutually 313 exclusive mechanisms. We show that androgen signaling influences activity of 11BHSD isozymes, 314 In our studies, most glucocorticoid-driven pathologies were found not to be androgen-dependent, 344
with the notable exception of glucocorticoid-induced hyperlipidemia. It has to be noted however 345 that Enzalutamide alone, independent of excessive CORT exposure, already lowered plasma lipid 346 levels. Also, Enzalutamide treatment resulted in increased testosterone levels, which via aromatase 347 can be converted to estradiol and provide metabolic benefit (Ohlsson, et al. 2017). Possibly a 348 protective role of estrogens, rather than a harmful role of androgens, may thus contribute to the 349 sexually dimorphic effects and cardiometabolic incidence. In support of this notion is that male and 350 female mice treated with estrogens were protected from the complications of high-fat diet feeding 351 (Dakin, et We show crosstalk between glucocorticoid and androgen signaling in metabolic tissues (Fig. 8) . 359
These potentially bidirectional interactions can dramatically differ between tissues, as we found 360 distinct patterns of nuclear receptor cooperation in the three different metabolic tissues that were 361 analyzed. Our novel findings provide a proof-of-concept that interactions between different nuclear 362 
